Cerberus Research Labs — Research Notes https://cerberusresearchlabs.com/blog/ Research-use-only notes on peptide science, handling, and the literature. Not medical advice; no human or veterinary use. en-us Fri, 04 Sep 2026 05:00:00 GMT https://cerberusresearchlabs.com/assets/brand/crl-logo-96.pngCerberus Research Labs — Research Noteshttps://cerberusresearchlabs.com/blog/ Reconstitution, Done Right: A Lab-Handling Walkthrough https://cerberusresearchlabs.com/blog/peptide-reconstitution-lab-handling/ https://cerberusresearchlabs.com/blog/peptide-reconstitution-lab-handling/ Fri, 04 Sep 2026 05:00:00 GMT Most research peptide material is lost between the vial and the pipette. A practical walkthrough of solvent choice, aseptic technique, concentration math, and post-reconstitution stability. Research use only. TB-500 and Thymosin Beta-4: What the Actin-Repair Research Actually Studies https://cerberusresearchlabs.com/blog/tb-500-thymosin-beta-4-research/ https://cerberusresearchlabs.com/blog/tb-500-thymosin-beta-4-research/ Wed, 26 Aug 2026 05:00:00 GMT A research overview of TB-500 and thymosin beta-4 — actin sequestration, the LKKTETQ motif, repair models, and why the two names are not interchangeable. RUO. GHK-Cu: What the Copper-Peptide Research Actually Studies https://cerberusresearchlabs.com/blog/ghk-cu-copper-peptide-research/ https://cerberusresearchlabs.com/blog/ghk-cu-copper-peptide-research/ Sun, 16 Aug 2026 05:00:00 GMT GHK-Cu is a copper-binding tripeptide isolated from human plasma in 1973. What the collagen, skin-remodeling, and wound-research literature actually studies — and its odd origin. RUO. How Snake Venom Became a Blood-Pressure Drug https://cerberusresearchlabs.com/blog/snake-venom-ace-inhibitor-origin/ https://cerberusresearchlabs.com/blog/snake-venom-ace-inhibitor-origin/ Sun, 16 Aug 2026 05:00:00 GMT The ACE-inhibitor class — one of the most-prescribed blood-pressure drug families — traces back to peptides in Brazilian pit viper venom. A research-history breakdown. RUO. Epitalon and the Longevity Peptides: What the Research Actually Studies https://cerberusresearchlabs.com/blog/epitalon-longevity-peptides/ https://cerberusresearchlabs.com/blog/epitalon-longevity-peptides/ Sat, 08 Aug 2026 05:00:00 GMT A research overview of Epitalon (AEDG) and the short peptide bioregulators — pineal origins, telomere and circadian research models, and how strong the evidence really is. RUO. NAD+ and Cellular-Energy Research: What the Science Actually Studies https://cerberusresearchlabs.com/blog/nad-cellular-energy-research/ https://cerberusresearchlabs.com/blog/nad-cellular-energy-research/ Wed, 05 Aug 2026 05:00:00 GMT A research overview of NAD+ — its role in redox metabolism, the sirtuin/PARP/CD38 enzymes that consume it, the salvage pathway, and what research models study. RUO. How to Read a Peptide Certificate of Analysis (COA) https://cerberusresearchlabs.com/blog/reading-a-peptide-coa/ https://cerberusresearchlabs.com/blog/reading-a-peptide-coa/ Tue, 04 Aug 2026 05:00:00 GMT A plain-English guide to reading a peptide Certificate of Analysis: what HPLC purity, mass spec identity, retention time, and lot numbers actually tell you — and the red flags that separate a real COA from a decorative one. RUO. Peptide Stability and the Cold Chain: A Lab-Handling Overview https://cerberusresearchlabs.com/blog/peptide-stability-cold-chain/ https://cerberusresearchlabs.com/blog/peptide-stability-cold-chain/ Wed, 29 Jul 2026 05:00:00 GMT A research-lab overview of peptide stability: why lyophilized peptides are shelf-stable, what happens to stability after reconstitution, and how temperature and storage practice affect research material integrity. RUO. The FDA Peptide Vote: Staff Said No, the Panel Said Yes https://cerberusresearchlabs.com/blog/fda-peptide-vote-explained/ https://cerberusresearchlabs.com/blog/fda-peptide-vote-explained/ Tue, 28 Jul 2026 05:00:00 GMT In July 2026 an FDA advisory committee voted 8–6–1 to recommend BPC-157 and KPV for the 503A compounding list — over staff objection. What it means. RUO. Cagrilintide and the Amylin Comeback https://cerberusresearchlabs.com/blog/cagrilintide-amylin-comeback/ https://cerberusresearchlabs.com/blog/cagrilintide-amylin-comeback/ Sat, 25 Jul 2026 05:00:00 GMT A research look at cagrilintide — the long-acting amylin-analog mechanism, and why it keeps appearing paired with GLP-1 agonists in study designs. RUO. BPC-157: What the Tissue-Repair Research Actually Studies https://cerberusresearchlabs.com/blog/bpc-157-tissue-repair-research/ https://cerberusresearchlabs.com/blog/bpc-157-tissue-repair-research/ Wed, 22 Jul 2026 05:00:00 GMT A research-focused look at BPC-157 — the angiogenesis, gut-lining and tendon models it appears in, and an honest RUO read on where the evidence stands. GLP-1 Peptides in 2026: The Research Landscape https://cerberusresearchlabs.com/blog/glp1-peptides-2026-research-landscape/ https://cerberusresearchlabs.com/blog/glp1-peptides-2026-research-landscape/ Tue, 21 Jul 2026 05:00:00 GMT A 2026 snapshot of GLP-1 peptide research — semaglutide, tirzepatide and retatrutide — how the class is studied and why it keeps adding receptors. RUO. Retatrutide and the Triple-Agonist Era https://cerberusresearchlabs.com/blog/retatrutide-triple-agonist-era/ https://cerberusresearchlabs.com/blog/retatrutide-triple-agonist-era/ Tue, 21 Jul 2026 05:00:00 GMT What a triple-agonist peptide is, why retatrutide sits at the frontier of metabolic research, and how the GLP-1/GIP/glucagon story fits together. RUO.